Evidence map›Paper›PMID 17361230›Full record

ReviewLeukemia2007

A tumor suppressor and oncogene: the WT1 story.

L Yang, Y Han, F Suarez Saiz, F Saurez Saiz, M D Minden

Erratum issuedAbstract readReview
PubMed Publisher
In one paragraph

Review in Leukemia, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 251 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
251citing papers in PubMed, 3 pooled it
13.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

251 citing papers in PubMed, 3 syntheses or guidelines pooled it, 474 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Translational pediatrics · 2025
    Article
  16. Article
  17. Review
  18. Insights into PediatricBiomedicines · 2025
    Review
  19. Article
  20. Article

191 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
    Saurez Saiz, F [corrected to Suarez Saiz, F]
5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

L YangDepartment of Cellular and Molecular Biology, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada.
Y Han
F Suarez Saiz
F Saurez Saiz
M D Minden
University Health Network · CAOntario Institute for Cancer Research · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Wilms' tumor 1 (WT1) gene encodes a transcription factor important for normal cellular development and cell survival. The initial discovery of WT1 as the causative gene in an autosomal-recessive condition identified it as a tumor suppressor gene whose mutations are associated with urogenital disease and the development of kidney tumors. However, this view is not in keeping with the frequent finding of wild-type, full-length WT1 in human leukemia, breast cancer and several other cancers including the majority of Wilms' tumors. Rather, these observations suggest that in those conditions, WT1 has an oncogenic role in tumor formation. In this review, we explore the literature supporting both views of WT1 in human cancer and in particular human leukemias. To understand the mechanism by which WT1 can do this, we will also examine its functional activity as a transcription factor and the influence of protein partners on its dual behavior.

Indexed as

Genes, Wilms TumorOncogenesCell DifferentiationCell SurvivalHematopoiesisHumansLeukemiaPrognosisWT1 ProteinsWT1 Proteins

Identifiers

PMID17361230
OpenAlexW1976615153

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.